Andrew Clamp Selected Research

Neoplasms (Cancer)

11/2020	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
11/2018	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.
10/2017	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
9/2010	Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew Clamp Research Topics

Disease

12	Ovarian Neoplasms (Ovarian Cancer) 02/2022 - 09/2010
4	Neoplasms (Cancer) 11/2020 - 09/2010
3	Ovarian Epithelial Carcinoma 02/2022 - 09/2010
3	Carcinoma (Carcinomatosis) 11/2020 - 10/2017
2	Endometrial Neoplasms (Endometrial Cancer) 01/2019 - 11/2015
2	Disease Progression 11/2018 - 11/2015
2	Neoplasm Metastasis (Metastasis) 10/2017 - 10/2004
1	Fallopian Tube Neoplasms 02/2022
1	Neutropenia 02/2022
1	Colorectal Neoplasms (Colorectal Cancer) 11/2018
1	Infections 10/2018
1	Vomiting 01/2017
1	Ascites 01/2017
1	Anemia 11/2015
1	Hyperglycemia 11/2015
1	Diarrhea 11/2015
1	Melanoma (Melanoma, Malignant) 12/2011
1	Bone Resorption 10/2004
1	Breast Neoplasms (Breast Cancer) 10/2002

Drug/Important Bio-Agent (IBA)

6	PlatinumIBA 01/2022 - 09/2010
4	Bevacizumab (Avastin)FDA Link 02/2022 - 09/2013
2	Carboplatin (JM8)FDA LinkGeneric 02/2022 - 07/2016
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 07/2016
2	olaparibIBA 01/2022 - 01/2018
2	liposomal doxorubicin (Doxil)FDA Link 01/2019 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 11/2018 - 10/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2018 - 09/2013
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2017 - 01/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2020
1	binimetinibIBA 11/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	Progesterone FDA LinkGeneric 01/2019
1	Anastrozole (Arimidex)FDA LinkGeneric 01/2019
1	Protein CoronaIBA 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Aromatase InhibitorsIBA 01/2019
1	Estrogens (Estrogen)FDA Link 01/2019
1	paragonIBA 01/2019
1	Liposomes (Liposome)IBA 01/2019
1	TabletsIBA 01/2018
1	AntigensIBA 10/2017
1	rucaparibIBA 10/2017
1	trebananibIBA 01/2017
1	1-dodecylpyridoxal (PLD)IBA 01/2017
1	ridaforolimusIBA 11/2015
1	MTOR InhibitorsIBA 11/2015
1	Progestins (Progestagens)IBA 11/2015
1	TOR Serine-Threonine KinasesIBA 11/2015
1	Endothelial Growth FactorsIBA 09/2013
1	MethyltransferasesIBA 12/2011
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 09/2010
1	Cisplatin (Platino)FDA LinkGeneric 09/2010
1	Cytotoxins (Cytolysins)IBA 09/2010
1	Collagen Type I (Type I Collagen)IBA 10/2004
1	Tamoxifen FDA LinkGeneric 10/2002

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 11/2020 - 12/2011
5	Therapeutics 02/2022 - 11/2015
1	Central Venous Catheters 10/2018
1	Chemoprevention 10/2002